Corporate Executive Summary IR

Investors / Corporate Executive Summary

Corporate Executive Summary

Innovation and Compassion has Earned us a Nobel Nomination and the Highest Pre-IPO Biotech Valuation of 2022

Personalized therapies are among the most impressive contributions of modern medicine, yet for decades their benefits have been limited to small patient populations. Equipped with breakthrough science, business experience, positive trial results for its pioneering off-the-shelf T cell product (TVGN 489), and a comprehensive research pipeline in virology, neurology, and oncology, Tevogen strives to achieve commercial success through developing affordable personalized medicines for large patient populations for the very first time.

Tevogen’s Disruptive Science: Inherent T-cell Receptors Without Genetic Modifications

Tevogen’s Assets: Science, Compassion, and Experience

  • Next generation precision T cell platform designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact
  • Robust and diversified R&D pipeline
  • Positive proof-of-concept clinical trial of first clinical product of company’s precision cell therapy platform
  • Strong intellectual property with multiple granted patents
  • Founder with Nobel Peace Prize nomination for business model innovation
  • Leadership with 250+ years of combined experience in science, biopharma, and business; providing the maturity of a corporation and the agility of a startup

Tevogen’s Future Milestones

The company is currently focused on accelerating the development of its lead product, TVGN 489, while augmenting the R&D portfolio in serious viral infections, viral-induced cancers, several non-virally induced common cancers, and neurologic disease (multiple sclerosis). Tevogen’s platform allows for selection and expansion of CD8+ T cells, capable of killing viral infected or malignant cells, allowing for treatment of hundreds of patients from a single donor. The recently completed proofof-concept clinical trial of TVGN 489 validates the utility and compelling potential of Tevogen’s precision T cell technology and cost-efficient manufacturing capability. Through development of Tevogen’s manufacturing and commercialization capacities, the company strives to bring personalized cell therapy to large patient populations for the very first time.


A team of senior industry leaders and preeminent scientists with extensive track records of drug development and global commercialization in almost all therapeutic areas. Tevogen has established its Corporate & Commercial Hub in Warren, New Jersey and its R&D Center and Preclinical Research Facility in Philadelphia within two years of formation of the company.

Please contact Tevogen Investor Relations for Corporate Overview

Forward-Looking Statements

This document contains certain forward-looking statements, including statements relating to Tevogen Bio®’s development of, the potential benefits of and patient access to its innovations in virology, oncology and neurology. Forward-looking statements may be able to be identified by words such as may, could, expect, possible, potential, goal, opportunity, and similar words or their opposites. These statements are based on management’s current expectations, assumptions, estimates, projections, and beliefs and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

In any forward-looking statement in which Tevogen Bio® Inc expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include, among others, risks related to the conduct and results of current or pending clinical trials, intellectual property protection, financial projections, and actions by the FDA/EMA.

Tevogen Bio® does not undertake an obligation to update the forward-looking statements, except as required by applicable laws.

© 2023 Tevogen Bio. All Rights Reserved.